LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

CytoSorbents Corp

Avatud

SektorTervishoid

1.15 -0.86

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.11

Max

1.19

Põhinäitajad

By Trading Economics

Sissetulek

6.4M

-1.5M

Müük

-423K

8.7M

Aktsiakasum

-0.144

Kasumimarginaal

-16.94

Töötajad

149

EBITDA

8.1M

-468K

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-15.25% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. aug 2025

Turustatistika

By TradingEconomics

Turukapital

24M

79M

Eelmine avamishind

2.01

Eelmine sulgemishind

1.15

Uudiste sentiment

By Acuity

67%

33%

338 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

CytoSorbents Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. juuni 2025, 23:49 UTC

Tulu

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. juuni 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. juuni 2025, 21:30 UTC

Tulu

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Tulu

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. juuni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. juuni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. juuni 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. juuni 2025, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. juuni 2025, 23:30 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. juuni 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. juuni 2025, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. juuni 2025, 22:06 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:15 UTC

Tulu

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. juuni 2025, 21:07 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. juuni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 20:52 UTC

Tulu

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. juuni 2025, 20:51 UTC

Tulu

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

CytoSorbents Corp Prognoos

Hinnasiht

By TipRanks

-15.25% langus

12 kuu keskmine prognoos

Keskmine 1 USD  -15.25%

Kõrge 1 USD

Madal 1 USD

Põhineb 1 Wall Streeti analüütiku instrumendi CytoSorbents Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.705 / 0.771Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

338 / 380 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.